Netflix, Inc. (Nasdaq: NFLX) has unveiled revealing, new information that confirms a sneaking suspicion— more than half (51%) of couples are likely to “cheat”1—but don’t start grilling your significant other or giving them the evil eye just yet.
A recent survey conducted by Harris Interactive on behalf of Netflix2 revealed 51% of those in a relationship would “cheat” on their spouse/partner/significant other by streaming a TV program(s) they agreed to watch together before their partner had a chance to watch it. More specifically, more than 28 million3 U.S. adults (12%) confessed they had already cheated and 10% admitted they had been “cheated on4.” It seems as though sometimes that next episode of your favorite series is just too tempting to wait for your partner. Sneaking around with that addictive little show may seem like a minor form of infidelity—but don’t be surprised if it leads to a few slamming doors and a bit of the silent treatment.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61735-netflix-survey-more-than-half-of-couples-consider-stream-cheating
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced its new WebMD Pain Coach™ for iPhone, a unique free mobile application for consumers and patients living with chronic pain. As the leader in mobile health, WebMD provides trusted health information anytime and anywhere with its mobile web and applications for consumers and physicians. The new WebMD Pain Coach™ app builds on WebMD’s market-leading mobile applications through a holistic approach that helps users create a balanced lifestyle.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57975-webmd-launches-unique-new-mobile-app-for-those-living-with-chronic-pain
Seattle’s Best Coffee, together with innovative food manufacturer Inventure Foods, Inc. (NASDAQ:SNAK)—the company responsible for bringing the “at home” frozen smoothie category to life in grocery store freezers three years ago—today unveiled Seattle’s Best Coffee® Frozen Coffee Blends, available in grocery, club and mass merchandise stores nationwide. Part of Starbucks corporation (NASDAQ: SBUX), Seattle’s Best brings great coffee to new and unexpected places. The blended coffee drink category continues to grow, with U.S. sales surging to $4.3 billion last year[1].
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62097-seattle-s-best-coffee-frozen-coffee-blends-at-home-frozen-smoothie
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, has announced the availability of an extensive set of advanced predictive sciences applications and services. These integrated capabilities enable drug discovery teams to investigate and evaluate hypotheses about the chemical or biological behavior of molecules of therapeutic interest in silico prior to costly experimentation. Accelrys predictive sciences leverages the open, scientifically aware Accelrys Enterprise Platform to deliver an advanced scientific decision support environment that reduces time and expense, improves quality, enhances collaboration and accelerates innovation in bringing new drugs to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62190-accelrys-offers-integrated-predictive-sciences-solutions-faster-innovation
Shire plc (LSE: SHP, NASDAQ: SHPG) has recently launched a new educational resource for people with diabetes and their caregivers as part of its HealTogether national awareness program. HealTogether.com is an online community designed to increase awareness and education of diabetic foot ulcers (DFUs) and help patients better understand that DFUs should be treated immediately.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62794-shire-launches-educational-resource-for-diabetes-and-caregivers
Building upon its efforts to provide greater access to vaccines and other health care services for populations in need, Walgreens (NYSE: WAG) (Nasdaq: WAG) is partnering with the United Nations Foundation this flu season, to help provide up to 3 million life-saving vaccines to children in developing countries through a donation to the Foundation’s Shot@Life campaign.
To view Multimedia News Release, go to http://www.multivu.com/players/English/62923-walgreens-flu-season2013
In recognition of Melanoma Monday® and National Melanoma/Skin Cancer Detection & Prevention MonthTM, MELA Sciences, Inc. (NASDAQ: MELA) visited the NASDAQ MarketSite in Times Square today to ring the Opening Bell and sponsor free skin cancer checks.
One American dies every hour from melanoma, the most deadly skin cancer. MELA Sciences, Inc. is the pioneer company behind MelaFind®, the first and only FDA-approved diagnostic tool that helps dermatologists detect melanoma at its most curable stage. MelaFind® was approved by the U.S. Food & Drug Administration (FDA) in Fall 2011, and since then has strategically rolled out the technology to dermatology practices across the country.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61584-mela-sciences-rings-opening-bell-awareness-melanoma-detection-prevention
Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the European Commission has granted marketing authorization to Constella® (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults . This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58658-almirall
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced that it has acquired Ireland-based QUMAS, a leading global provider of Cloud-based and on-premises enterprise compliance software supporting regulatory and quality operations in life sciences and other highly regulated industries. The QUMAS acquisition further extends Accelrys’ informatics portfolio with the addition of mission-critical, end-to-end document and process management compliance solutions. Proven quality management solutions supported by robust content and business process management capabilities provided by QUMAS advance Accelrys’ ability to help customers better manage the scientific innovation lifecycle by reducing regulatory risks, lowering quality costs, improving compliance effectiveness and increasing operational efficiency in bringing new products to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62188-accelrys-acquires-compliance-and-quality-management-leader-qumas
iGATE CEO Cup has created a thrilling format for a charitable tournament with CEOs representing many of the world's top companies playing for a noble cause.
iGATE, the NASDAQ-listed leading outsourcing services company, in association with Forbes, publisher of Forbes magazine and forbes.com, take the second iGATE CEO Cup Golf tournament international. This first-class championship-style golf tournament will be held March 21 – 22, 2014, at Course No. 2 and Course No. 8 of the legendary Pinehurst Resort & Country Club in North Carolina, USA. Grand Slam champion Gary Player will co-host the iGATE CEO Cup just as he did for the inaugural tournament last year.
To view Multimedia News Release, go to http://www.multivu.com/players/English/51359-iGate-CEO-cup-charitable-tournament/
As a new survey conducted online by Harris Interactive on behalf of Nutrisystem among over 3,000 U.S adults in December, indicates more than half of Americans (54 percent) are planning to make New Year’s resolutions to lose weight. Nutrisystem (NASDAQ: NTRI), the leading provider of home-delivered weight loss meal plans, is gearing up to help them succeed in keeping those resolutions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59643-nutrisystem-survey-weight-loss-new-year-s-resolutions
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
